Skip to Content
Merck
  • Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer.

Molecular therapy : the journal of the American Society of Gene Therapy (2014-05-06)
Maria Angelica Cortez, David Valdecanas, Xiaochun Zhang, Yanai Zhan, Vikas Bhardwaj, George A Calin, Ritsuko Komaki, Dipak K Giri, Caio C Quini, Tatiana Wolfe, Heidi J Peltier, Andreas G Bader, John V Heymach, Raymond E Meyn, James W Welsh
ABSTRACT

The microRNA (miR)-200s and their negative regulator ZEB1 have been extensively studied in the context of the epithelial-mesenchymal transition. Loss of miR-200s has been shown to enhance cancer aggressiveness and metastasis, whereas replacement of miR-200 miRNAs has been shown to inhibit cell growth in several types of tumors, including lung cancer. Here, we reveal a novel function of miR-200c, a member of the miR-200 family, in regulating intracellular reactive oxygen species signaling and explore a potential application for its use in combination with therapies known to increase oxidative stress such as radiation. We found that miR-200c overexpression increased cellular radiosensitivity by direct regulation of the oxidative stress response genes PRDX2, GAPB/Nrf2, and SESN1 in ways that inhibits DNA double-strand breaks repair, increase levels of reactive oxygen species, and upregulate p21. We used a lung cancer xenograft model to further demonstrate the therapeutic potential of systemic delivery of miR-200c to enhance radiosensitivity in lung cancer. Our findings suggest that the antitumor effects of miR-200c result partially from its regulation of the oxidative stress response; they further suggest that miR-200c, in combination with radiation, could represent a therapeutic strategy in the future.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1H-1,2,3-Triazole, 97%
Sigma-Aldrich
Anti-NS3 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution